We can’t show the full text here under this license.
Abstract
A 62-year-old woman developed new-onset atrial fibrillation after starting tirzepatide treatment.
- Tirzepatide is used for type 2 diabetes and obesity but may be associated with rare cardiac rhythm disturbances.
- The patient experienced palpitations, low blood pressure, and a rapid heart rate that required intensive medical intervention.
- No underlying heart disease, electrolyte issues, or hormonal disorders were found during examination.
- Atrial fibrillation did not return after stopping tirzepatide, suggesting a possible link between the medication and the arrhythmia.
- Vigilance for cardiac arrhythmias is important when initiating new incretin-based therapies.
Simplified